XTX Topco Ltd Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS)

XTX Topco Ltd increased its stake in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) by 37.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,412 shares of the biopharmaceutical company’s stock after buying an additional 19,831 shares during the quarter. XTX Topco Ltd’s holdings in Arbutus Biopharma were worth $253,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ABUS. Vanguard Group Inc. boosted its holdings in Arbutus Biopharma by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company’s stock valued at $29,367,000 after purchasing an additional 62,282 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Arbutus Biopharma by 900.4% in the fourth quarter. JPMorgan Chase & Co. now owns 896,258 shares of the biopharmaceutical company’s stock valued at $2,931,000 after purchasing an additional 806,672 shares during the last quarter. Franklin Resources Inc. purchased a new stake in Arbutus Biopharma in the fourth quarter valued at $301,000. Woodline Partners LP boosted its holdings in Arbutus Biopharma by 45.4% in the fourth quarter. Woodline Partners LP now owns 971,628 shares of the biopharmaceutical company’s stock valued at $3,177,000 after purchasing an additional 303,475 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Arbutus Biopharma in the fourth quarter valued at $662,000. 43.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on ABUS. Wall Street Zen raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating in a report on Saturday. Chardan Capital reaffirmed a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Monday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Arbutus Biopharma presently has an average rating of “Buy” and an average price target of $5.50.

Arbutus Biopharma Stock Performance

Shares of Arbutus Biopharma stock opened at $3.35 on Tuesday. The firm has a 50-day simple moving average of $3.32 and a two-hundred day simple moving average of $3.31. The company has a market cap of $642.20 million, a P/E ratio of -11.55 and a beta of 0.86. Arbutus Biopharma Corporation has a fifty-two week low of $2.70 and a fifty-two week high of $4.72.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. The business had revenue of $10.74 million during the quarter, compared to the consensus estimate of $2.21 million. Arbutus Biopharma had a negative net margin of 352.24% and a negative return on equity of 59.28%. Equities research analysts forecast that Arbutus Biopharma Corporation will post -0.39 EPS for the current year.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.